BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Entered two new OEM programs through agreement with Level 4 platform partner with expected SOP in 2026; Met operational target of 2-3 additional customer programs in ...

Dawson Geophysical Company (NASDAQ: DWSN) (the "Company") today reported unaudited financial results for its third ...

dosages of the Pfizer-BioNTech vaccine. Other vaccines (such as Moderna) were excluded from analyses. The final older (12-17 ...

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

Moderna chief executive officer Stéphane Bancel steps down as chief commercial officer, with president Stephen Hoge assuming ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Arbutus Biopharma Corp (ABUS) showcases significant progress in hepatitis B treatment and maintains a robust cash runway into ...

How are the new vaccines different from last fall’s boosters? The updated mRNA vaccines from Moderna and Pfizer-BioNTech target the KP.2 strain, part of the Omicron lineage that began spreading last ...